{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:59:01Z","timestamp":1767664741132,"version":"3.40.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40266-023-01023-7","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T19:46:19Z","timestamp":1682019979000},"page":"397-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-2580","authenticated-orcid":false,"given":"Gabriel","family":"Antherieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Falandry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"1023_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm1963","volume":"7","author":"V Schreiber","year":"2006","unstructured":"Schreiber V, Dantzer F, Ame J-C, et al. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7:517\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1023_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/356356a0","volume":"356","author":"MS Satoh","year":"1992","unstructured":"Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature. 1992;356:356\u20138.","journal-title":"Nature"},{"key":"1023_CR3","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1038\/sj.onc.1206679","volume":"22","author":"K Valerie","year":"2003","unstructured":"Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene. 2003;22:5792\u2013812.","journal-title":"Oncogene"},{"key":"1023_CR4","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152\u20138.","journal-title":"Science"},{"key":"1023_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"1023_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol. 2015;33:244\u201350.","journal-title":"J Clin Oncol"},{"key":"1023_CR7","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","volume":"21","author":"G Kim","year":"2015","unstructured":"Kim G, Ison G, McKee AE, et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21:4257\u201361.","journal-title":"Clin Cancer Res"},{"key":"1023_CR8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"1023_CR9","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154\u201364.","journal-title":"N Engl J Med"},{"key":"1023_CR10","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"1023_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet"},{"key":"1023_CR12","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15-28.","journal-title":"Lancet Oncol"},{"key":"1023_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","volume":"122","author":"J Farre\u015b","year":"2013","unstructured":"Farre\u015b J, Mart\u00edn-Caballero J, Mart\u00ednez C, et al. Parp-2 is required to maintain hematopoiesis following sublethal \u03b3-irradiation in mice. Blood. 2013;122:44\u201354.","journal-title":"Blood"},{"key":"1023_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","volume":"17","author":"TA Hopkins","year":"2019","unstructured":"Hopkins TA, Ainsworth WB, Ellis PA, et al. PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol Cancer Res. 2019;17:409\u201319.","journal-title":"Mol Cancer Res"},{"key":"1023_CR15","doi-asserted-by":"publisher","first-page":"7485","DOI":"10.2169\/internalmedicine.7485-21","volume":"61","author":"D Himeji","year":"2022","unstructured":"Himeji D, Tanaka G, Shiiba R, et al. Pneumocystis pneumonia in a patient with ovarian cancer receiving olaparib therapy. Intern Med. 2022;61:7485\u2013521.","journal-title":"Intern Med"},{"key":"1023_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256205","volume":"16","author":"JC Andreu-Ballester","year":"2021","unstructured":"Andreu-Ballester JC, Pons-Castillo A, Gonz\u00e1lez-S\u00e1nchez A, et al. Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality. PLoS ONE. 2021;16: e0256205.","journal-title":"PLoS ONE"},{"key":"1023_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","volume":"7","author":"C M\u00e9n\u00e9trier-Caux","year":"2019","unstructured":"M\u00e9n\u00e9trier-Caux C, Ray-Coquard I, Blay J-Y, et al. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer. 2019;7:85.","journal-title":"J Immunother Cancer"},{"key":"1023_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s10147-018-1374-4","volume":"24","author":"Y Yoshino","year":"2019","unstructured":"Yoshino Y, Taguchi A, Takao M, et al. Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer. Int J Clin Oncol. 2019;24:428\u201336.","journal-title":"Int J Clin Oncol"},{"key":"1023_CR19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/cam4.1956","volume":"8","author":"YJ Lee","year":"2019","unstructured":"Lee YJ, Chung YS, Lee J-Y, et al. Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer. Cancer Med. 2019;8:564\u201371.","journal-title":"Cancer Med"},{"key":"1023_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3109\/07357900009012191","volume":"18","author":"EC Dees","year":"2000","unstructured":"Dees EC, O\u2019reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 2000;18:521\u20139.","journal-title":"Cancer Invest"},{"key":"1023_CR21","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1038\/sj.emboj.7601301","volume":"25","author":"J Y\u00e9lamos","year":"2006","unstructured":"Y\u00e9lamos J, Monreal Y, Saenz L, et al. PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes. EMBO J. 2006;25:4350\u201360.","journal-title":"EMBO J"},{"key":"1023_CR22","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/cdd.2014.202","volume":"22","author":"J Farr\u00e9s","year":"2015","unstructured":"Farr\u00e9s J, Llacuna L, Martin-Caballero J, et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ. 2015;22:1144\u201357.","journal-title":"Cell Death Differ"},{"key":"1023_CR23","doi-asserted-by":"publisher","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","volume":"366","author":"S Jaiswal","year":"2019","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366:eaan4673. https:\/\/doi.org\/10.1126\/science.aan4673.","journal-title":"Science"},{"key":"1023_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.coi.2011.05.006","volume":"23","author":"CM Woolthuis","year":"2011","unstructured":"Woolthuis CM, de Haan G, Huls G. Aging of hematopoietic stem cells: Intrinsic changes or micro-environmental effects? Curr Opin Immunol. 2011;23:512\u20137.","journal-title":"Curr Opin Immunol"},{"key":"1023_CR25","doi-asserted-by":"publisher","first-page":"9194","DOI":"10.1073\/pnas.0503280102","volume":"102","author":"DJ Rossi","year":"2005","unstructured":"Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci. 2005;102:9194\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"1023_CR26","doi-asserted-by":"publisher","first-page":"11075","DOI":"10.1038\/ncomms11075","volume":"7","author":"A Grover","year":"2016","unstructured":"Grover A, Sanjuan-Pla A, Thongjuea S, et al. Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells. Nat Commun. 2016;7:11075. https:\/\/doi.org\/10.1038\/ncomms11075.","journal-title":"Nat Commun"},{"key":"1023_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017487","volume":"6","author":"CE R\u00fcbe","year":"2011","unstructured":"R\u00fcbe CE, Fricke A, Widmann TA, et al. Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. PLoS ONE. 2011;6: e17487. https:\/\/doi.org\/10.1371\/journal.pone.0017487.","journal-title":"PLoS ONE"},{"key":"1023_CR28","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1182\/blood-2009-03-212688","volume":"114","author":"HJM de Jonge","year":"2009","unstructured":"de Jonge HJM, de Bont ESJM, Valk PJM, et al. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood. 2009;114:2869\u201377.","journal-title":"Blood"},{"key":"1023_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2021.111615","volume":"157","author":"H Sun","year":"2022","unstructured":"Sun H, Kang X, Chen X, et al. Immunosenescence evaluation of peripheral blood lymphocyte subsets in 957 healthy adults from 20 to 95 years old. Exp Gerontol. 2022;157: 111615.","journal-title":"Exp Gerontol"},{"key":"1023_CR30","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol"},{"key":"1023_CR31","first-page":"PA2586","volume":"54","author":"D Biondini","year":"2019","unstructured":"Biondini D, Semenzato U, Bonato M, et al. Lymphopenia is linked to an increased incidence of cancer in smokers without COPD. Eur Respir J. 2019;54:PA2586.","journal-title":"Eur Respir J"},{"key":"1023_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16526","volume":"2","author":"DA Zidar","year":"2019","unstructured":"Zidar DA, Al-Kindi SG, Liu Y, et al. Association of lymphopenia with risk of mortality among adults in the US general population. JAMA Netw Open. 2019;2: e1916526.","journal-title":"JAMA Netw Open"},{"key":"1023_CR33","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","volume":"27","author":"A Niroula","year":"2021","unstructured":"Niroula A, Sekar A, Murakami MA, et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021;27:1921\u20137.","journal-title":"Nat Med"},{"key":"1023_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/geront\/4.4.195","volume":"4","author":"RL Walford","year":"1964","unstructured":"Walford RL. The immunologic theory of aging. Gerontologist. 1964;4:195\u20137.","journal-title":"Gerontologist"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-023-01023-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:11:56Z","timestamp":1744715516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-023-01023-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1007\/s40266-023-01023-7","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"type":"print","value":"1170-229X"},{"type":"electronic","value":"1179-1969"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"13 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Claire Falandry reported personal fees from Leo Pharma, Pfizer, MSD Oncology, Teva, AstraZeneca, Baxter, Eisai, Janssen Oncology, Novartis, Chugai Pharma and Astellas Pharma outside the submitted work; grants from Chugai Pharma, Pfizer, Pierre Fabre and Astellas Pharma outside the submitted work; and non-financial support from Janssen Oncology, Pierre Fabre, AstraZeneca and Leo Pharma outside the submitted work. Gabriel Antherieu, Ma\u00ebl Heiblig, Herv\u00e9 Ghesquieres, and Gilles Freyer declare they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients included in this study provided informed consent regarding data collection and publication of the corresponding results. This study was approved by the Scientific and Ethical Committee of Hospices Civils de Lyon (N\u00b0 22-5014) and was registered in accordance with local guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available due to ethical and privacy reasons but are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Conceptualization: GA, CF, MH. Methodology: GA, CF, MH. Validation: GA, CF, MH. Formal analysis: GA, CF. Investigation: GA, CF. Resources: CF. Data curation: GA, CF. Writing\u2014original draft preparation: GA, CF. Writing\u2014review and editing: GA, CF, GF, HG, MH. Supervision: CF, MH. Project administration: GA, CF. Funding acquisition: Not applicable. All authors have read and agreed to the published version of this manuscript. Every person involved in this analysis was offered authorship.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}